Session Information

  • WCLC 2022

    2022 World Conference on Lung Cancer

    Conference Program for 2022 the World Conference on Lung Cancer

    Presentation Date(s):  
    • August 6 - 9, 2022
    • Total Presentations: 2137

    All times listed are in Vienna, Austria Time, CEST (UTC+2:00)

    PL - Plenary
    IBS - Interactive Breakfast Session (in-person attendees only)
    ES - Education Session
    OA - Oral Session
    MA - Mini Oral Session
    P - Posters
    EP - ePosters
    WS - Workshops
    LA – Lectureship Awards
    IS - Industry Symposium

Filter Results:

Show Only CME Accredited Sessions

  • +

    OA03 - Molecular Targeted Treatments

    • 14:30 - 15:40
    • 8/07/2022
    • Location: Hall C7
    • Not for CME Credit
    • Type: Oral
    • Track: Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments
    • +

      Session Moderator

      15:32 - 15:40  |  Presenter: Andrew Ciupek

      • Abstract

      Loading...

    • +

      Session Moderator

      15:32 - 15:40  |  Presenter: David R. Gandara

      • Abstract

      Loading...

    • +

      OA03.01 - Session Introduction

      14:30 - 14:31  |  Presenter: Andrew Ciupek

      • Abstract

      Loading...

    • +

      OA03.02 - Session Introduction

      14:31 - 14:32  |  Presenter: David R. Gandara

      • Abstract

      Loading...

    • +

      OA03.03 - Sotorasib in Combination with RMC-4630, a SHP2 Inhibitor, in KRAS p.G12C-Mutated NSCLC and Other Solid Tumors

      14:32 - 14:42  |  Presenter: Gerald Falchook

      • Abstract

      Loading...

    • +

      OA03.04 - Phase I A Study to Evaluate GDC-6036 Monotherapy in Patients with Non-small Cell Lung Cancer (NSCLC) with KRAS G12C Mutation

      14:42 - 14:52  |  Presenter: Adrian Sacher

      • Abstract

      Loading...

    • +

      OA03.05 - Tepotinib in Patients with MET Exon 14 (METex14) Skipping NSCLC: Primary Analysis of the Confirmatory VISION Cohort C

      14:52 - 15:02  |  Presenter: Michael Thomas

      • Abstract

      Loading...

    • +

      OA03.06 - CodeBreaK 100/101: First Report of Safety/Efficacy of Sotorasib in Combination with Pembrolizumab or Atezolizumab in Advanced KRAS p.G12C NSCLC

      15:02 - 15:12  |  Presenter: Bob T. Li

      • Abstract

      Loading...

    • +

      OA03.07 - Safety and Efficacy of D-1553 in Patients with KRAS G12C Mutated Non-Small Cell Lung Cancer: A Phase 1 Trial

      15:12 - 15:22  |  Presenter: Shun Lu

      • Abstract

      Loading...

    • +

      OA03.08 - Discussant

      15:22 - 15:32  |  Presenter: Helena Linardou

      • Abstract

      Loading...

    • +

      OA03.09 - Live Q&A

      15:32 - 15:40

      • Abstract

      Loading...

  • +

    P1.09 - Global Health, Health Services Research, and Health Economics - Support to Patients and Staff

    • 17:00 - 19:00
    • 8/07/2022
    • Location: Exhibit Hall - Hall B
    • Not for CME Credit
    • Type: Regular Poster
    • Track: Global Health, Health Services Research, and Health Economics - Support to Patients and Staff
    • +

      P1.09-01 - The Lung Cancer Patient Experience and Care Pathway: A Multi-Country Survey

      Presenter: Pauline Frank

      • Abstract

      Loading...

  • +

    P1.12 - Management of Lung Cancer in the Era of COVID-19

    • 17:00 - 19:00
    • 8/07/2022
    • Location: Exhibit Hall - Hall B
    • Not for CME Credit
    • Type: Regular Poster
    • Track: Management of Lung Cancer in the Era of COVID-19
    • +

      P1.12-01 - Lung Cancer Screening in the COVID-19 Era: Understanding Program-Level Impact

      Presenter: Andrew Ciupek

      • Abstract

      Loading...

  • +

    P2.08 - Patient Advocacy

    • 17:15 - 19:15
    • 8/08/2022
    • Location: Exhibit Hall - Hall B
    • Not for CME Credit
    • Type: Regular Poster
    • Track: Patient Advocacy
    • +

      P2.08-01 - Real-world barriers to clinical trial enrollment as reported by U.S. lung cancer patients and community cancer centers

      Presenter: Andrew Ciupek

      • Abstract

      Loading...